Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 19/20 | 0.69 |
| ▸ | PDE4A | P27815 | 13/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25205204 | 1.00 | PDE4B (0.69) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL9937865 | 0.92 | PDE4B (0.58) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL710230 | 0.89 | PDE4B (0.55) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL825653 | 0.89 | PDE4B (0.53) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL4426112 | 0.87 | PDE4B (0.52) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL6025567 | 0.86 | PDE4B (0.64) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1583109 | 0.85 | PDE4B (0.66) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL22043707 | 0.84 | PDE4B (0.79) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL21750072 | 0.84 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL4428840 | 0.84 | PDE4B (0.62) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3188745-A1 | DOSAGE TITRATION OF APREMILAST FOR THE TREATMENT OF DISEASES AMELIORATED BY PDE4 INHIBITION | Celgene Corporation (US) | 2017-07-12 | — | — | EP | claimed |
| EP-3157520-A1 | APREMILAST FOR THE TREATMENT OF A LIVER DISEASE OR A LIVER FUNCTION ABNORMALITY | Celgene Corporation (US) | 2017-04-26 | — | — | EP | claimed |
| EP-3096749-A1 | METHODS FOR THE TREATMENT OF OBESITY USING APREMILAST | Celgene Corporation (US) | 2016-11-30 | — | — | EP | claimed |
| WO-2016025686-A1 | DOSAGE TITRATION OF APREMILAST FOR THE TREATMENT OF DISEASES AMELIORATED BY PDE4 INHIBITION | CELGENE CORPORATION (US) | 2016-02-18 | — | — | WO | claimed |
| WO-2015200177-A1 | APREMILAST FOR THE TREATMENT OF A LIVER DISEASE OR A LIVER FUNCTION ABNORMALITY | CELGENE CORPORATION (US) | 2015-12-30 | — | — | WO | claimed |
| WO-2015112568-A1 | METHODS FOR THE TREATMENT OF OBESITY USING APREMILAST | CELGENE CORPORATION (US) | 2015-07-30 | — | — | WO | claimed |
| WO-2014151180-A1 | TREATMENT OF PSORIATIC ARTHRITIS USING APREMILAST | CELGENE CORPORATION (US) | 2014-09-25 | — | — | WO | claimed |
| EP-2683376-A2 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | Celgene Corporation (US) | 2014-01-15 | — | — | EP | claimed |
| EP-2498753-A2 | NANOSUSPENSION OF A POORLY SOLUBLE DRUG MADE BY MICROFLUIDIZATION PROCESS | Celgene Corporation (US) | 2012-09-19 | — | — | EP | claimed |
| WO-2012121988-A2 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2012-09-13 | — | — | WO | claimed |
| WO-2011059931-A2 | NANOSUSPENSION OF A POORLY SOLUBLE DRUG VIA MICROFLUIDIZATION PROCESS | CELGENE CORPORATION (US) | 2011-05-19 | — | — | WO | claimed |
| US-20080207730-A1 | Reducing tumor necrosis factor; phosphodiesterase inhibitor;anticancer agents; leukemia; antidepressants; antiinflammatory agents; skin disorders; inflammatory bowel disease; Crohn's disease | CELGENE CORPORATION | 2008-08-28 | — | — | US | claimed |
| EP-1485087-A1 | (+)-2- 1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2004-12-15 | — | — | EP | claimed |
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | AMGEN INC. | 2003-10-02 | — | — | US | claimed |
| WO-2003080049-A1 | (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | claimed |
| WO-2003080048-A1 | (-)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | claimed |
| US-20200399386-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CELGENE CORPORATION | 2020-12-24 | — | — | US | disclosed |
| WO-2017175087-A1 | PROCESS FOR PREPARATION OF AMORPHOUS APREMILAST | INTAS PHARMACEUTICALS LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
| EP-1126839-A1 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNF ALPHA LEVELS | CELGENE CORPORATION (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025777-A1 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNFαLEVELS | CELGENE CORPORATION (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | PDE4A, PDE2A, PDE3A | PDE4B 6/4885PDE4C 8/4885PDE4A 1/4885 |
| US-20200399386-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CD79B, BCL6, CD22 | PDE4B 4638/4885PDE4C 4515/4885PDE4A 4566/4885 |
| US-20080207730-A1 | Reducing tumor necrosis factor; phosphodiesterase inhibitor;anticancer agents; leukemia; antidepressants; antiinflammatory agents; skin disorders; inflammatory bowel disease; Crohn's disease | TNF, PDE4A, PDE3A | PDE4B 4/4885PDE4C 8/4885PDE4A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.